Education
About Us
Working with TipRanks
Follow Us
Else Nutrition Holdings Inc (TSE:BABY)
:BABY
RESEARCH TOOLSreports
BABY Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$0.01 - C$0.21
Previous CloseN/A
Volume122.00K
Average Volume (3M)497.60K
Market Cap
C$6.81M
Enterprise ValueC$23.90M
Total Cash (Recent Filing)C$375.00K
Total Debt (Recent Filing)C$1.64M
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Jul 19, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding340,368,320
10 Day Avg. Volume0
30 Day Avg. Volume497,595
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)7.30
Price to Sales (P/S)0.00
P/FCF Ratio-7.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Else Nutrition Holdings Inc News
PremiumCompany Announcements
Else Nutrition Faces Cease Trade Order and AGM Extension Amid Filing Delays
PremiumCompany Announcements
Else Nutrition Poised for Growth Amid U.S. Infant Formula Regulatory ReformsPremiumCompany Announcements
Else Nutrition’s 2024 Financial Results and Strategic Outlook
PremiumCompany Announcements
Else Nutrition Navigates Challenges and Prepares for Growth in 2025
PremiumCompany Announcements
Else Nutrition Expands U.S. Retail Presence with Kids RTD Shakes
PremiumCompany Announcements
Else Nutrition Reports on Bi-Weekly Default Status Amid Audit DelaysPremiumCompany Announcements
Else Nutrition Reports on Bi-Weekly Default Status Amid Audit DelaysOptions Prices
Currently, No data available
---
Ownership Overview
―
Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
BABY FAQ
What was Else Nutrition Holdings Inc’s price range in the past 12 months?
Else Nutrition Holdings Inc lowest stock price was C$0.01 and its highest was C$0.20 in the past 12 months.
What is Else Nutrition Holdings Inc’s market cap?
Else Nutrition Holdings Inc’s market cap is C$6.81M.
When is Else Nutrition Holdings Inc’s upcoming earnings report date?
Else Nutrition Holdings Inc’s upcoming earnings report date is Jul 19, 2025 which is in 14 days.
How were Else Nutrition Holdings Inc’s earnings last quarter?
Currently, no data Available
Is Else Nutrition Holdings Inc overvalued?
According to Wall Street analysts Else Nutrition Holdings Inc’s price is currently Overvalued.
Does Else Nutrition Holdings Inc pay dividends?
Else Nutrition Holdings Inc does not currently pay dividends.
What is Else Nutrition Holdings Inc’s EPS estimate?
Else Nutrition Holdings Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Else Nutrition Holdings Inc have?
Else Nutrition Holdings Inc has 340,368,320 shares outstanding.
What happened to Else Nutrition Holdings Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Else Nutrition Holdings Inc?
Currently, no hedge funds are holding shares in TSE:BABY
Company Description
Else Nutrition Holdings Inc
Else Nutrition Holdings Inc (BABY) is a Canadian-based company operating in the food and beverage sector, specifically focusing on the development, production, and marketing of plant-based food products for infants, toddlers, children, and adults. The company is known for its innovative, clean-label, and dairy-free nutritional products, which serve as alternatives to traditional dairy-based formulas and snacks. Else Nutrition's flagship products include its plant-based toddler nutrition and complementary products aimed at addressing various dietary needs.
BABY Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook for Else Nutrition. While there are positive signs such as revenue growth, cost reduction efforts, and expansion in retail and online channels, the company faces challenges including sequential revenue decline, limited marketing budgets, negative gross profit, and delays in FDA approvals. The company is actively working on securing funding and partnerships to overcome these challenges.Read More>